drugset / Trial / NCT07076199

A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

NCT07076199

Phase 3 Recruiting 877 enrolled Novo Nordisk A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

This study compares insulin icodec, an insulin taken once a week to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 1 diabetes. The study will look at how well insulin icodec taken weekly controls blood sugar compared to insulin glargine taken daily. The study will last for about 8.5 months.

Timeline

Start
2025-08-11
Primary completion
2027-01-25
Completion
2027-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin icodec Protein / enzyme biologic Subcutaneous
Comparator insulin glargine Protein / enzyme biologic Subcutaneous
Background insulin aspart Protein / enzyme biologic Subcutaneous